Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2013 | Letter to the Editor

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a ¹²³I-FP-CIT study: reply to comment by Erro et al.

Authors: Daniela Di Giuda, Giovanni Camardese, Fabrizio Cocciolillo, Alfonso Fasano

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2013

Excerpt

Dear Sir, …

Erro R, Pappatà S, Barone P, Pellecchia MT. Comment on Di Giuda et al.: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-012-2300-z.

Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2012;39:1937–48. doi:10.1007/s00259-012-2232-7.PubMedCrossRef

Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–32.PubMed

Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23:1580–7.PubMedCrossRef

Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY. Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson’s disease. J Neural Transm. 2000;107(3):303–19.PubMedCrossRef

Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS, et al.; PROMS-PD study group. Parkinson’s disease motor subtypes and mood. Mov Disord. 2012;27(3):379–86. doi:10.1002/mds.24041.PubMedCrossRef

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.PubMedCrossRef

Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P. Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord. 2011;26(3):407–15. doi:10.1002/mds.23184.PubMedCrossRef

Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007;22(8):1077–92.PubMedCrossRef

Title: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al.
Authors: Daniela Di Giuda
Giovanni Camardese
Fabrizio Cocciolillo
Alfonso Fasano
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2303-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a ¹²³I-FP-CIT study: reply to comment by Erro et al.

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2013

Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI)

Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride

Value of 11C-methionine PET in imaging brain tumours and metastases

Predicting tumour response to chemoradiotherapy in oesophageal cancer by early interim 18F-FDG PET: where do we stand and where should we go?

PET/MR imaging of the pelvis in the presence of endoprostheses: reducing image artifacts and increasing accuracy through inpainting

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma